Lesch-Nyhan syndrome laboratory findings

Jump to navigation Jump to search

Lesch-Nyhan syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lesch-Nyhan syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Lesch-Nyhan syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lesch-Nyhan syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lesch-Nyhan syndrome laboratory findings

CDC on Lesch-Nyhan syndrome laboratory findings

Lesch-Nyhan syndrome laboratory findings in the news

Blogs on Lesch-Nyhan syndrome laboratory findings

Directions to Hospitals Treating Lesch-Nyhan syndrome

Risk calculators and risk factors for Lesch-Nyhan syndrome laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Overview

When an affected individual has fully developed the three clinical elements of uric acid overproduction which is neurologic dysfunction, and cognitive and behavioral disturbances, diagnosis of LNS is easily made. Difficulties of diagnosis are abundant in the early stages when the three features are not yet obvious. Suspicion often comes about when the developmental delay of the individual is associated with hyperuricemia.

Laboratory Findings

Blood tests

Urinalysis

Biochemical Testing

  • Biochemical analyses, although not routinely performed, on hair bulbs from at risk women have had a small number of both false positive and false negative outcomes.
  • If only a suspected carrier female is available for HGPRT1 mutation testing, it is appropriate to grow her lymphocytes in 6-thioguanine (a purine analogue), which allows only HGPRT-deficient cells to survive.
  • A mutant frequency of 0.5-5.0 x 10-2 is found in carrier females, while a non-carrier female has a frequency of 1-20 x 10-6. This frequency is usually diagnostic by itself.
  • Molecular genetic testing is the most effective method of testing, as HGPRT1 is the only gene known to be associated with LNS. *Individuals who display the full Lesch-Nyhan phenotype all have mutations in the HGPRT1 gene. Sequence analysis of mRNA is available clinically and can be utilized in order to detect HGPRT1 mutations in males affected with Lesch-Nyhan syndrome. *Techniques such as RT-PCR, multiplex genomic PCR, and sequence analysis (cDNA and genomic DNA), used for the diagnosis of genetic diseases, are performed on a research basis. If RT-PCR tests result in cDNA showing the absence of an entire exon or exons, then multiplex genomic PCR testing is performed. Multiplex genomic PCR testing amplifies the nine exons of the HGPRT1 gene as eight PCR products.
  • If the exon in question is deleted, the corresponding band will be missing from the multiplex PCR. However if the exon is present, the exon is sequenced to identify the mutation, therefore causing exclusion of the exon from cDNA. If no cDNA is created by RT-PCR, then multiplex PCR is performed on the notion that most or all of the gene is obliterated.

Other tests

  • Activity of HGPRT enzyme fibroblastss or lymphoblasts that is less than 1.5% of normal enzyme activity confirms the diagnosis of Lesch-Nyhan syndrome.

References

Template:WH Template:WS